RE: BURBLE11 Sep 2020 21:00
Inanco, You are correct. What I see may be very different from other's views. As you will note from another post, I still look forward to the time when pancreatic cancer survival rates are on par with other cancers rather than the meagre 5-8% rate (which is up in 2 years from 3-4%). And from yet another post, there is much work to do, and it is Scancell who must determine which paths they chose to take.
With so many investors to attract who would value a welcoming, safe place to learn to learn about Scancell, and debate issues, I will continue to search for other options to this site. The share price is now within striking distance of the current TD valuation, which is a point of joy.
ATB for the weekend.